Cargando…
Clonal architectures predict clinical outcome in clear cell renal cell carcinoma
The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated extensively but its evolution patterns remained unclear. Here we analyze the clonal architectures of 473 patients from three different populations. We find that the mutational signatures vary substantially across...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423009/ https://www.ncbi.nlm.nih.gov/pubmed/30886153 http://dx.doi.org/10.1038/s41467-019-09241-7 |
_version_ | 1783404460943343616 |
---|---|
author | Huang, Yi Wang, Jiayin Jia, Peilin Li, Xiangchun Pei, Guangsheng Wang, Changxi Fang, Xiaodong Zhao, Zhongming Cai, Zhiming Yi, Xin Wu, Song Zhang, Baifeng |
author_facet | Huang, Yi Wang, Jiayin Jia, Peilin Li, Xiangchun Pei, Guangsheng Wang, Changxi Fang, Xiaodong Zhao, Zhongming Cai, Zhiming Yi, Xin Wu, Song Zhang, Baifeng |
author_sort | Huang, Yi |
collection | PubMed |
description | The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated extensively but its evolution patterns remained unclear. Here we analyze the clonal architectures of 473 patients from three different populations. We find that the mutational signatures vary substantially across different populations and evolution stages. The evolution patterns of ccRCC have great inter-patient heterogeneities, with del(3p) being regarded as the common earliest event followed by three early departure points: VHL and PBRM1 mutations, del(14q) and other somatic copy number alterations (SCNAs) including amp(7), del(1p) and del(6q). We identify three prognostic subtypes of ccRCC with distinct clonal architectures and immune infiltrates: long-lived patients, enriched with VHL but depleted of BAP1 mutations, have high levels of Th17 and CD8(+) T cells while short-lived patients with high burden of SCNAs have high levels of Tregs and Th2 cells, highlighting the importance of evaluating evolution patterns in the clinical management of ccRCC. |
format | Online Article Text |
id | pubmed-6423009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-64230092019-03-20 Clonal architectures predict clinical outcome in clear cell renal cell carcinoma Huang, Yi Wang, Jiayin Jia, Peilin Li, Xiangchun Pei, Guangsheng Wang, Changxi Fang, Xiaodong Zhao, Zhongming Cai, Zhiming Yi, Xin Wu, Song Zhang, Baifeng Nat Commun Article The genetic landscape of clear cell renal cell carcinoma (ccRCC) had been investigated extensively but its evolution patterns remained unclear. Here we analyze the clonal architectures of 473 patients from three different populations. We find that the mutational signatures vary substantially across different populations and evolution stages. The evolution patterns of ccRCC have great inter-patient heterogeneities, with del(3p) being regarded as the common earliest event followed by three early departure points: VHL and PBRM1 mutations, del(14q) and other somatic copy number alterations (SCNAs) including amp(7), del(1p) and del(6q). We identify three prognostic subtypes of ccRCC with distinct clonal architectures and immune infiltrates: long-lived patients, enriched with VHL but depleted of BAP1 mutations, have high levels of Th17 and CD8(+) T cells while short-lived patients with high burden of SCNAs have high levels of Tregs and Th2 cells, highlighting the importance of evaluating evolution patterns in the clinical management of ccRCC. Nature Publishing Group UK 2019-03-18 /pmc/articles/PMC6423009/ /pubmed/30886153 http://dx.doi.org/10.1038/s41467-019-09241-7 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Huang, Yi Wang, Jiayin Jia, Peilin Li, Xiangchun Pei, Guangsheng Wang, Changxi Fang, Xiaodong Zhao, Zhongming Cai, Zhiming Yi, Xin Wu, Song Zhang, Baifeng Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title | Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title_full | Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title_fullStr | Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title_full_unstemmed | Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title_short | Clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
title_sort | clonal architectures predict clinical outcome in clear cell renal cell carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423009/ https://www.ncbi.nlm.nih.gov/pubmed/30886153 http://dx.doi.org/10.1038/s41467-019-09241-7 |
work_keys_str_mv | AT huangyi clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT wangjiayin clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT jiapeilin clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT lixiangchun clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT peiguangsheng clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT wangchangxi clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT fangxiaodong clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT zhaozhongming clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT caizhiming clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT yixin clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT wusong clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma AT zhangbaifeng clonalarchitecturespredictclinicaloutcomeinclearcellrenalcellcarcinoma |